Skip to main content

Peyronie Disease Responds to New Medical Treatment


May 30, 2012 — Collagenase Clostridium histolyticum (CCh) alleviates many symptoms of Peyronie disease, according to the findings of a phase 2b randomized, double-blind, placebo-controlled trial.
Martin Gelbard, MD, from Urology Associates Medical Group in Burbank, California, and colleagues published their findings in the June 2012 issue of the Journal of Urology.
The authors note that there is a need for additional nonsurgical treatments for Peyronie disease. "Surgery is the standard of care for moderate to severe cases of [Peyronie disease] unresponsive to medical therapy," they write. "However, surgery is only recommended for patients with sexual dysfunction in the stable phase of disease since complications include penile shortening, sensory change, recurrent penile curvature and [erectile dysfunction]."
To assess the efficacy of CCh, the authors recruited 147 patients from 12 American sites. They stratified patients by degree of penile curvature (30 - 60° or >60°) and randomly assigned them for treatment with either CCh or placebo (3:1 randomization), with or without penile plaque modeling (1:1 randomization). CCh treatment improved curvature by 29.7% (mean change, −16.3° ± 14.65°) compared with an improvement of 11% (mean change, −5.4 ± 13.8°) in the placebo group (P = .001).
For each treatment cycle, patients received 2 injections of CCh (0.58 mg or 10,000 U) or placebo, separated by 24 to 72 hours, and treatment was repeated after 6 weeks for a maximum of 6 treatment cycles. The authors measured penile length and curvature using calipers and assessed the effects of Peyronie disease on patient quality of life and penile function, using the Peyronie disease patient-reported outcome (PD-PRO) and International Index of Erectile Function (IIEF) questionnaires, respectively.
Among patients who underwent penile plaque modeling, patients treated with CCh exhibited a 32.4% improvement in penile curvature (mean change, − 17.5° ± 15.3°) compared with a 2.5% worsening (mean change, 0.6° ± 13.2°) in the placebo group (P < .001). Conversely, among nonmodeled patients, no difference was observed in the change in penile curvature between the CCh and placebo groups (27.1% vs 27.9%, respectively).
Among the modeled patients, those treated with CCh had a significantly higher mean improvement in the PD-PRO symptom bother domain score compared with placebo (mean change, −3.6° vs −0.1°, respectively; P = .004), whereas no change was observed among nonmodeled patients (−1.5° vs −1.5°, respectively). Moreover, among the modeled patients, CCh treatment was associated with a significant mean improvement in the IIEF overall sexual satisfaction score compared with placebo (P = .04).
Adverse events were significantly more common among CCh-treated patients, including bruising (P < .001), edema (P < .001), pain (P < .001), contusion (P = .07), penile pain (P = .07), and penile edema (P = .07). However, most adverse events were mild to moderate in severity. The limitations of the study included the use of a fixed prostaglandin E1 dose to induce erection before measurements and the learning curve of the investigators regarding the injection technique.
The authors indicate that additional studies are underway to better clarify the efficacy of this treatment. "[The r]esults suggest that CCh should be considered a viable treatment option" for patients with Peyronie disease, they write. "Placebo controlled, phase 3 studies of [Peyronie disease]...are currently ongoing to provide additional safety and efficacy information."
John P. Mulhall, MD, from the Memorial Sloan-Kettering Cancer Center in New York City, indicated that this agent may soon be available for clinical use. "This early phase study demonstrates promising results for this intralesional agent," Dr. Mulhall told Medscape Medical News by email. "Phase III trials with 600 men enrolled will be completed soon, and it is hoped that the data will be presented to the [US Food and Drug Administration] in 2012 with hopes for an approval in 2013."
Dr. Gelbard has a financial interest and/or other relationship with Auxilium and Biospecifics. One coauthor has a financial interest and/or other relationship with Allergan, Auxilium, American Medical Systems, and Repros Therapeutics. Three coauthors are employed by Auxilium. One coauthor has a financial interest and/or other relationship with Auxilium, Coloplast, Lilly, Astellas, Pfizer, and American Medical Systems. Dr. Mulhall has disclosed no relevant financial relationships.

Comments

  1. Unknown13 November 2013 at 02:15

    This the excellent post which I have seen and it helped me a lot , Thanks for sharing it!!
    peyronies treatment

    ReplyDelete

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

FDA Decision Delayed for Truvada in HIV PrEP

June 11, 2012 — The US Food and Drug Administration (FDA) has delayed its decision on allowing the use of tenofovir disoproxil fumarate/emtricitabine ( Truvada , Gilead) as preexposure prophylaxis (PrEP) so that the proposed risk evaluation and mitigation strategy (REMS) can be reviewed. In early May, the FDA's Antiviral Drugs Advisory Committee  strongly backed  approval of the first-ever drug for the prevention of sexually acquired HIV-1 infection. However, concerns by the panel at the time included that people may neglect condom use if they feel they are protected by PrEP. Panelists were also concerned that uninfected people taking PrEP who become infected with HIV may not switch to a 3-drug regimen as recommended. According to the company, the FDA has postponed the target date to September 14 so it can review Gilead's REMS plan to help ensure that patients will not misuse the drug. The committee's recommendation for supplemental approval of tenofovir/emtricit...
Post a Comment
Read more

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...
Post a Comment
Read more